We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
+12.43%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$334M
AUM Growth
-$6.26M
Cap. Flow
-$20.2M
Cap. Flow %
-6.04%
Top 10 Hldgs %
55.99%
Holding
67
New
24
Increased
10
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$12.9M
2
INCY icon
Incyte
INCY
+$8.26M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$8.02M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.82M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$7.23M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$17.4M
2
ACLX
Arcellx
ACLX
+$14.7M
3
IMCR icon
Immunocore
IMCR
+$11.5M
4
MRK icon
Merck
MRK
+$10.2M
5
IMVT icon
Immunovant
IMVT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.38%
2 Financials 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
1
Syndax Pharmaceuticals
SNDX
$2.02B
$33.3M 9.98%
1,731,191
+319,015
+23% +$6.59M
ROIV icon
2
Roivant Sciences
ROIV
$24.8B
$32M 9.57%
2,769,819
+57,078
+2% +$650K
MRUS
3
DELISTED
Merus
MRUS
$21M 6.3%
421,222
+132,554
+46% +$6.92M
IMVT icon
4
Immunovant
IMVT
$8.27B
$19.1M 5.73%
671,001
-340,878
-34% -$10.1M
ARQT icon
5
Arcutis Biotherapeutics
ARQT
$3.56B
$16.5M 4.95%
1,778,318
+812,926
+84% +$8.02M
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
$15.8M 4.74%
1,481,809
-13,238
-0.9% -$144K
BMY icon
7
Bristol-Myers Squibb
BMY
$124B
$14.2M 4.26%
+275,303
New +$12.9M
APLT
8
DELISTED
Applied Therapeutics
APLT
$13.2M 3.96%
1,554,586
-656,734
-30% -$3.87M
CRNX icon
9
Crinetics Pharmaceuticals
CRNX
$8.88B
$10.9M 3.27%
213,815
-337,280
-61% -$17.4M
BHVN icon
10
Biohaven
BHVN
$2.32B
$10.8M 3.24%
216,440
-16,815
-7% -$654K
PRAX icon
11
Praxis Precision Medicines
PRAX
$8.77B
$10M 3%
174,034
+144,775
+495% +$7.82M
AUTL
12
Autolus Therapeutics
AUTL
$383M
$9.5M 2.84%
2,616,602
-46,130
-2% -$184K
INCY icon
13
Incyte
INCY
$23.4B
$8.56M 2.56%
+129,490
New +$8.26M
DNLI icon
14
Denali Therapeutics
DNLI
$3.7B
$8.22M 2.46%
282,050
+31,040
+12% +$769K
DAWN
15
DELISTED
Day One Biopharmaceuticals
DAWN
$7.06M 2.11%
+506,978
New +$7.23M
SLRN
16
DELISTED
ACELYRIN
SLRN
$6.5M 1.95%
+1,317,854
New +$6.8M
SLNO
17
DELISTED
Soleno Therapeutics
SLNO
$6.22M 1.86%
+123,177
New +$5.9M
CABA icon
18
Cabaletta Bio
CABA
$461M
$6.03M 1.81%
1,278,444
+100,339
+9% +$581K
IMTX icon
19
Immatics
IMTX
$1.31B
$5.13M 1.54%
449,735
-52,472
-10% -$621K
KROS icon
20
Keros Therapeutics
KROS
$211M
$5.05M 1.51%
+86,930
New +$4.29M
ACLX
21
DELISTED
Arcellx
ACLX
$5.02M 1.5%
60,076
-220,633
-79% -$14.7M
VTGN icon
22
VistaGen Therapeutics
VTGN
$9.4M
$4.9M 1.47%
1,846,792
-1,790
-0.1% -$6.11K
NRIX icon
23
Nurix Therapeutics
NRIX
$2.4B
$4.56M 1.37%
203,015
-258
-0.1% -$5.84K
TCRX icon
24
TScan Therapeutics
TCRX
$59.8M
$4.29M 1.28%
860,951
+15,882
+2% +$95.8K
ZURA icon
25
Zura Bio
ZURA
$518M
$4.24M 1.27%
+1,044,168
New +$3.9M
1
2 3

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Stempoint Capital held 67 positions worth $334M, down 1.8% from $340M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Stempoint Capital withdrew a net $20.2M in Q3 2024, closing 13 positions and reducing 18 holdings. Its most notable exit was Immunocore, an estimated $11.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Bristol-Myers Squibb worth $14.2M.

  • Stempoint Capital's largest Q3 2024 buy was Bristol-Myers Squibb: 275,303 shares worth $14.2M.
  • Stempoint Capital added most to Arcutis Biotherapeutics in Q3 2024, an estimated $8.02M increase.
  • Stempoint Capital's biggest Q3 2024 reduction was Crinetics Pharmaceuticals, cutting an estimated $17.4M.
  • Stempoint Capital fully exited Immunocore in Q3 2024, selling an estimated $11.5M.
  • Stempoint Capital's ten largest holdings make up 56% of its $334M portfolio in Q3 2024.
  • Stempoint Capital opened 24 new positions and closed 13 in Q3 2024.
  • Stempoint Capital's portfolio value fell 1.8% quarter-over-quarter to $334M.

Based on Stempoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.